Showing results (1501-1510 of 1,669) with videos related to

Sort By:
Pageof 167
British Journal of Haematology|December 12, 2001
Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapseT I Mughal, A Yong, R M Szydlo, et al.
Radiology|November 21, 2007
Adrenal masses: characterization with in vivo proton MR spectroscopy--initial experienceJuliano F Faria, Suzan M Goldman, Jacob Szejnfeld, et al.
Journal of Vascular Surgery|August 5, 2000
Early inflammatory response after elective abdominal aortic aneurysm repair: a comparison between endovascular procedure and conventional surgeryC Galle, V De Maertelaer, S Motte, et al.
Lancet (London, England)|September 18, 1982
Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemiaJ M Goldman, A S Baughan, D M McCarthy, et al.
Clinical and Experimental Immunology|March 1, 1982
T-chronic lymphocytic leukaemia presenting as primary hypogammaglobulinaemia--evidence of a proliferation of T-suppressor cellsS L Thien, D Catovsky, D Oscier, et al.
Blood|September 9, 1999
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of HematologyR T Silver, S H Woolf, R Hehlmann, et al.
Texas Heart Institute Journal|December 16, 2024
Impact of Atrial Fibrillation Type on Outcomes of Transcatheter Aortic Valve Replacement for Aortic Stenosis: A Single-Center AnalysisYoshiyuki Yamashita, Serge Sicouri, Massimo Baudo, et al.
Blood|December 23, 1999
Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study GroupA Hochhaus, A Reiter, S Saussele, et al.
Leukemia|February 11, 2005
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapseD Marin, J Kaeda, R Szydlo, et al.
Blood|October 17, 2008
Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomibAgnes S M Yong, Keyvan Keyvanfar, Nancy Hensel, et al.
Pageof 167